[Federal Register Volume 86, Number 26 (Wednesday, February 10, 2021)]
[Notices]
[Page 8929]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02688]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Meeting 
Notice

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) will convene a 
meeting of the Advisory Committee on the Medical Uses of Isotopes 
(ACMUI) on March 16, 2021. A sample of agenda items to be discussed 
during the public session includes: An overview of fiscal year 2020 
medical related events; a discussion on the status of the NRC's patient 
release evaluation of emerging brachytherapy sources; a discussion on 
calibration procedures for existing and emerging brachytherapy sources; 
a discussion on the current ACMUI reporting structure; and an overview 
on the consequences of radiopharmaceutical extravasation and 
therapeutic interventions in nuclear medicine. The agenda is subject to 
change. The current agenda and any updates will be available on the 
ACMUI's Meetings and Related Documents web page at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2021.html or by emailing Ms. 
Kellee Jamerson at the contact information below.

DATES: Date and Time for Open Session: Tuesday, March 16, 2021, from 
10:00 a.m. to 3:45 p.m. EST.

ADDRESSES: 

------------------------------------------------------------------------
                   Date                          Webinar information
------------------------------------------------------------------------
March 16, 2021............................  Link: https://usnrc.webex.com.
                                            Event number: 199 910 9533.
------------------------------------------------------------------------

    Public Participation: Due to the ongoing COVID-19 public health 
emergency, the meeting will be held as a webinar using Cisco WebEx. Any 
member of the public who wishes to participate in any portion of this 
meeting should register in advance of the meeting by accessing the 
provided link above. Upon successful registration, a confirmation email 
will be generated providing the telephone bridge line and a link to 
join the webinar on the day of the meeting. Members of the public 
should also monitor the NRC's Public Meeting Schedule at https://www.nrc.gov/pmns/mtg for any meeting updates. If there are any 
questions regarding the meeting, persons should contact Ms. Jamerson 
using the information below.

FOR FURTHER INFORMATION CONTACT: Ms. Kellee Jamerson, email: 
[email protected], telephone: 301-415-7408.

SUPPLEMENTARY INFORMATION: 
    Purpose: Discuss issues related to 10 CFR part 35 Medical Use of 
Byproduct Material.

Conduct of the Meeting

    The ACMUI Chair, Darlene F. Metter, M.D., will preside over the 
meeting. Dr. Metter will conduct the meeting in a manner that will 
facilitate the orderly conduct of business. The following procedures 
apply to public participation in the meeting:
    1. Persons who wish to provide a written statement should submit an 
electronic copy to Ms. Jamerson using the contact information listed 
above. All submittals must be received by the close of business on 
March 10, 2021 and must only pertain to the topics on the agenda.
    2. Questions and comments from members of the public will be 
permitted during the meeting, at the discretion of the ACMUI Chairman.
    3. The draft transcript and meeting summary will be available on 
ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2021.html on or about May 3, 2021.
    4. Persons who require special services, such as those for the 
hearing impaired, should notify Ms. Jamerson of their planned 
participation.
    This meeting will be held in accordance with the Atomic Energy Act 
of 1954, as amended (primarily Section 161a); the Federal Advisory 
Committee Act (5 U.S.C. App); and the Commission's regulations in Title 
10 of the Code of Federal Regulations, Part 7.

    Dated at Rockville, Maryland this 4th day of February, 2021.

    For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2021-02688 Filed 2-9-21; 8:45 am]
BILLING CODE 7590-01-P